ArticleAntimicrobial agents and chemotherapy2008
Antibacterial efficacy of R-type pyocins towards Pseudomonas aeruginosa in a murine peritonitis model.
Article in Antimicrobial agents and chemotherapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it, 102 citations in OpenAlex.
- Antibacterial and antibiofilm activities of pyocins produced byFrontiers in microbiology · 2026Pooled it
- Prophage-Derived Molecules as Anti-Antibiotics (Basel, Switzerland) · 2026Review
- Synergistic Bactericidal Effects of R- and F-Type Pyocin Cocktails Against ClinicalAntibiotics (Basel, Switzerland) · 2026Article
- R pyocin sensitivity ofJournal of medical microbiology · 2026Article
- Identification of an R1-type pyocin previously misannotated as a prophage inMicrobiology (Reading, England) · 2026Article
- Functional characterization of Pseudomonas soli VMAP1 as a biocontrol agent against Xanthomonas vesicatoria in tomato plants.Scientific reports · 2026Article
- Identification and functional insights into new phage tail-like bacteriocins targetingMicrobiology spectrum · 2026Article
- Lipopolysaccharide-targeting treatments for multidrug-resistantExpert opinion on therapeutic targets · 2026Review
- TattleTail: A Rule-Based Tool for Identifying Canonical Pyocin-Encoding Gene Clusters inComputational and structural biotechnology journal · 2026Article
- Genomic correlates of tailocin sensitivity in Pseudomonas syringae.G3 (Bethesda, Md.) · 2025Article
- Role of R5 pyocin in the predominance of high-risk Pseudomonas aeruginosa isolates.Microbiological research · 2025Article
- R-pyocins as targeted antimicrobials against Pseudomonas aeruginosa.npj antimicrobials and resistance · 2025Review
- A VersaTile Approach to Reprogram the Specificity of the R2-Type Tailocin Towards Different Serotypes ofAntibiotics (Basel, Switzerland) · 2025Article
- EF-hand calcium sensor, EfhP, controls transcriptional regulation of iron uptake by calcium inmBio · 2024Article
- Bacteriocins: potentials and prospects in health and agrifood systems.Archives of microbiology · 2024Review
- Engineering ofCells · 2023Article
- F-Type Pyocins Are Diverse Noncontractile Phage Tail-Like Weapons for KillingJournal of bacteriology · 2023Article
- Comprehensive Approaches for the Search and Characterization of Staphylococcins.Microorganisms · 2023Article
- Study of 32 new phage tail-like bacteriocins (pyocins) from a clinical collection of Pseudomonas aeruginosa and of their potential use as typing markers and antimicrobial agents.Scientific reports · 2023Article
- Evolutionary and ecological role of extracellular contractile injection systems: from threat to weapon.Frontiers in microbiology · 2023Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
R-type pyocins are high-molecular-weight bacteriocins carried within the chromosomes of some bacterial species, such as Pseudomonas aeruginosa, and almost certainly evolved from lysogenic bacteriophages of the Myoviridae family. They contain no head structures and no DNA and are used as defense systems, usually against other strains of the same bacterial species. They bind with their tail fibers to targeted bacterial surface molecules and then kill by inserting a core or needle that dissipates the bacterial membrane potential. Their mechanism of action, high bactericidal potency (one pyocin particle can kill one bacterium), and focused spectrum suggest that R-type pyocins could be developed as antibacterial agents. In a lethal mouse peritonitis model, submicrogram quantities of pyocin prevent death from 90% lethal dose inocula of a pyocin-sensitive, clinical isolate of P. aeruginosa. We show here the dose response curves, treatment windows, or periods of response after infection and the several-log-unit acute reduction of bacterial load in blood and spleen samples, suggesting that R-type pyocins have several characteristics that one would expect from an effective therapeutic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.